AZILECT® (rasagiline tablets) is contraindicated with meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, cyclobenzaprine, or another (selective or non-selective) MAOI. Read More Important Safety Information

Parkinson’s Support Solutions® helps your patients start and stay on AZILECT

Parkinson's Support Solutions (PSS) has a number of financial options that can help your patients whether they have commercial insurance, carry Medicare, or are uninsured.

PSS also offers a range of educational materials to help patients manage their Parkinson’s disease and understand AZILECT therapy.

Parkinson’s Support Solutions®

Benefits evaluation
  • Verification of AZILECT coverage under current plan
  • Low-Income Subsidy eligibility (Medicare patients only)
Medicare Part D open enrollment assistance when choosing a plan
  • Medicare Part D open enrollment is October 15 to December 7
Co-pay assistance
  • Eligibility evaluation and communication with pharmacy if requested
Patient assistance programs
  • Eligibility determination and help with application process
Pharmacy troubleshooting
Educational materials

Download and print the registration form in English and Spanish.

Bring patients together with support today.
Phone 1-866-880-8582 | Fax 1-866-920-0001

AZILECT® (rasagiline tablets) is indicated for the treatment of Parkinson’s disease (PD).

  • AZILECT is contraindicated with meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, cyclobenzaprine, or another (selective or non-selective) MAOI
  • Exacerbation of hypertension may occur during treatment with AZILECT. Monitor patients for new-onset hypertension or hypertension that is not adequately controlled after starting AZILECT
  • Dietary tyramine restriction is not required during treatment with recommended doses of AZILECT. However, patients should be advised to avoid foods containing a very high amount of tyramine because of the potential for severe increases in blood pressure, also referred to as hypertensive urgency, crisis, or emergency
  • Concomitant use of AZILECT and antidepressants is not recommended; serotonin syndrome has been reported with concomitant use with an antidepressant or MAO inhibitors
  • Patients treated with AZILECT and other dopaminergic medications have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles. Prescribers should monitor patients for drowsiness or sleepiness
  • Patients with moderate to severe hepatic impairment should not take AZILECT. AZILECT should not exceed 1 mg/day or 0.5 mg/day for patients with mild hepatic impairment or in patients using ciprofloxacin or another CYP1A2 inhibitor
  • Patients receiving AZILECT with adjunct therapy have reported orthostatic hypotension, especially in the first two months of treatment
  • Dyskinesia (or exacerbations of dyskinesia), hallucinations or psychotic-like behavior, impulse control or compulsive behaviors, withdrawal-emergent hyperpyrexia/confusion, and melanoma are potentially associated with AZILECT
  • The most common side effects as monotherapy (AZILECT 1 mg, placebo, respectively [%]) include flu syndrome (5, 1), arthralgia (7, 4), depression (5, 2), and dyspepsia (7, 4)
  • The most common side effects as adjunct to dopamine agonists (AZILECT 1 mg, placebo, respectively [%]) include peripheral edema (7, 4), fall (6, 1), arthralgia (5, 2), cough (4, 1), and insomnia (4, 1)
  • The most common side effects as adjunct to levodopa therapy (AZILECT 1 mg, 0.5 mg, and placebo, respectively [%]) include dyskinesia (18, 18, 10), accidental injury (12, 8, 5), weight loss (9, 2, 3), postural hypotension (9, 6, 3), vomiting (7, 4, 1), anorexia (5, 2, 1), arthralgia (8, 6, 4), abdominal pain (5, 2, 1), nausea (12, 10, 8), constipation (9, 4, 5), dry mouth (6, 2, 3), rash (6, 3, 3), abnormal dreams (4, 1, 1), fall (11, 12, 8), and tenosynovitis (3, 1, 0)
  • Please see full Prescribing Information.